Over the last several years, the FDA and other regulatory agencies have issued mandates, guidance, and laws regarding the need to increase diversity in clinical trial design. But what will these new requirements really entail for sites, sponsors and CROs? This group of experts will give insights into what the industry needs to know about current and future requirements for diverse participant inclusion and engagement.